Bio-Thera Solutions Reports the NMPA's Acceptance of MAA for BAT1806 (biosimilar, tocilizumab) to Treat Rheumatoid Arthritis
Shots:
- The NMPA has accepted the marketing authorization application for BAT1806, a biosimilar of Roche’s Actemra (tocilizumab) for the treatment of patients with arthritis
- In June 2021, the results from the P-III study of BAT1806 showed equivalent efficacy and comparable safety to the originator in patients with moderate-to-severe RA
- Tocilizumab is an immunosuppressive drug that acts on the receptor of the inflammatory cytokine receptor, IL-6 & is used for the treatment of inflammatory conditions including RA and systemic JIA. In June' 2021, the US FDA has granted a EUA for the treatment of COVID-19 in the US & is sold under the brand name Actemra
Ref: Businesswire | Image: Bio-Thera
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com